The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity.

Beta Bionics’ IPO marks one of the largest public offerings for an Orange County-based company in over three years, second ...

The spot “is a clear violation” of the FDCA, “which requires that advertising for prescription drugs — including compounded ...